Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Amortizatization of Intangibles (2016 - 2025)

Historic Amortizatization of Intangibles for Heron Therapeutics (HRTX) over the last 13 years, with Q3 2025 value amounting to $130000.0.

  • Heron Therapeutics' Amortizatization of Intangibles fell 7605.89% to $130000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year decrease of 5521.55%. This contributed to the annual value of $2.1 million for FY2024, which is 2323.17% up from last year.
  • As of Q3 2025, Heron Therapeutics' Amortizatization of Intangibles stood at $130000.0, which was down 7605.89% from $239000.0 recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Amortizatization of Intangibles registered a high of $638000.0 during Q1 2024, and its lowest value of -$104000.0 during Q1 2022.
  • Its 5-year average for Amortizatization of Intangibles is $356058.8, with a median of $361000.0 in 2023.
  • As far as peak fluctuations go, Heron Therapeutics' Amortizatization of Intangibles plummeted by 12071.71% in 2022, and later surged by 318181.82% in 2023.
  • Heron Therapeutics' Amortizatization of Intangibles (Quarter) stood at $283000.0 in 2021, then surged by 102.83% to $574000.0 in 2022, then fell by 1.39% to $566000.0 in 2023, then crashed by 31.27% to $389000.0 in 2024, then crashed by 66.58% to $130000.0 in 2025.
  • Its Amortizatization of Intangibles was $130000.0 in Q3 2025, compared to $239000.0 in Q2 2025 and $281000.0 in Q1 2025.